MALEKIGORJI, M., KONG THOO LIN, P., LEES, M., GUEORGUIEVA, M., CURTIS, A., & HOSKINS, C. 2016. Thermally triggered theranostics for pancreatic cancer. Presented at 24th biennial European Association for Cancer Research congress 2016 (EACR24), 9-12 July 2016, Manchester, UK.

Thermally triggered theranostics for pancreatic cancer.


MALEKIGORJI, M., KONG THOO LIN, P., LEES, M., GUEORGUIEVA, M., CURTIS, A., & HOSKINS, C.

2016



This document was downloaded from https://openair.rgu.ac.uk






Thermally Triggered Theranostics for Pancreatic Cancer

Maryam Malekigorji^a, Paul Kong Thoo Lin^b, Martin Lees^c, Mariana Gueorguieva^d, Anthony Curtis^a, Clare Hoskins^a ^a Institute for Science and Technology in Medicine, School of Pharmacy, Hornbeam Building Keele, ST5 6DB, ^b Physics Department, University of Warwick, Coventry, CV4 7AL, UK, ^c

School of Life Sciences and Pharmacy, Robert Gordon University, Aberdeen, AB24 1HG, UK, ^d Institute for Medical Science and Technology, University of Dundee, DD2 1FD, UK

Introduction

- this treatment as well as exploring alternative therapies.
- applicable in biomedicine (Fig. 1).



within each layer.

- carrier potentials.
- intercalation (Fig. 2)





Figure 2. Basic bisnaphthalimide chemical structure.

for pancreatic cancer.

The formulations cytoxicity was determined using MTT assay and trypan blue exclusion on human pancreatic adenocarcinoma (BxPC-3) cells (Fig. 6A). The data showed a significant reduction in IC50 after drug conjugation onto HNPs compared with free drug. RGD was added onto the formulation to confer a targeting effect, however, this did not have any significant effect on the IC₅₀ values observed (Fig. 6B) Cellular uptake studies also showed that increased drug content was achievable after conjugation (Fig. 6D), after conjugation of the RGD s significant increase in drug was achieved in the PEGylated formulations.



liquid chromatography both C) without and D) with the presence of a cyclic RGD targeting peptide.

cytotoxicity (Fig. 7D).




Figure 7. AFM topographical analysis of fixed BxPC-3 cells after exposure to A) cell culture media (control), B) free drug (4 charges), C) uncoated HNPs and D) HNP-drug (4 charges) for 4h.

Laser irradiation of HNPs (50 µgmL⁻¹) in vitro over 60 sec showed a temperature rise of 9 degrees (Fig. 8A). 4 h after irradiation the cells were fixed and imaged for topography showing no structural damage (Fig. 8B). This suggests these particles could be exploited in thermally triggered drug release. The threshold energy required drug *in vitro* is being investigated.

This work highlights the multifunctional nature of hybrid nanoparticles for use in image guided triggered drug delivery. Further work is on-going to evaluate the in vivo potential of these systems in pancreatic cancer xenograft models.



Results

Figure 6. Cytotoxicity testing of novel formulations on BxPC-3 cells measured by MTT assay and trypan blue exclusion both A) without and B) with attachement of a cyclic RGD targeting peptide. Cellular uptake of drug molecules measured by high performance

Cellular morphology after exposure to the free drugs (4 charges) and HNP formulations (4 charges) was assessed after 4 h using AFM. The images show that after this sort time the cells exposed to the free drug (Fig. 7B) or uncoated HNPs (Fig. 7C) do not exhibit any morphological changes and look healthy, whereas the cells exposed to the novel formulations look to be undegoing cellular breakdown as a result of the increased




Figure 8. A) Laser irradiation of HNPs in vitro (50 µgmL⁻¹) and B)

imaging of cellular morphology using AFM 4 h post irradiation.

Conclusion